← Back to Search

Imaging

MRI Scans for Chronic Lung Disease

N/A
Recruiting
Led By Grace E Parraga, PhD
Research Sponsored by Western University, Canada
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subjects male and female aged 18-75 with diagnosed lung disease including but not limited to: asthma, emphysema, Chronic Obstructive Pulmonary Disease (COPD), bronchiectasis, sarcoidosis, pulmonary fibrosis, alpha 1-anti-trypsin deficiency, lymphangioleiomyomatosis (LAM) and Bronchiolitis obliterans organizing pneumonia (BOOP)
Subject must be able to perform a breathhold for 16s
Must not have
Subject with a contraindication to Magnetic Resonance Imaging (i.e. ferrous implants, cardiac pacemakers). This will be determined through a screening form
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will scan men and women aged 18-85 who have lung disease using MRI, to measure their lung function.

Who is the study for?
This trial is for men and women aged 18-75 with various lung diseases who can hold their breath for 16 seconds, have an FEV1 >25% predicted, and a Forced Vital Capacity (FVC) >25% predicted. Participants must understand the study and consent to join. Exclusions include having metal implants or conditions that prevent MRI use like severe claustrophobia.
What is being tested?
The study tests how well Magnetic Resonance Imaging (MRI) using hyperpolarized helium can show changes in lungs of chronic lung disease patients over time by measuring things like Apparent Diffusion Coefficient (ADC), ventilation defects, and percent ventilation.
What are the potential side effects?
There are generally no side effects associated with undergoing an MRI scan itself; however, some individuals may experience discomfort from holding their breath or lying still during the procedure.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18-75 years old with a diagnosed lung condition.
Select...
I can hold my breath for 16 seconds.
Select...
I can perform lung function tests consistently.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I cannot have an MRI due to having metal implants or a pacemaker.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Lung function as measured using inhaled gas MRI ventilation defect percent (VDP)
Secondary study objectives
Lung microstructure as measured using inhaled gas MRI Apparent Diffusion Coefficients (ADC)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: MRI at baseline and over timeExperimental Treatment1 Intervention
Patients with chronic lung disease will undergo pulmonary function tests, hyperpolarized Helium and or Xenon MRI at each visit.

Find a Location

Who is running the clinical trial?

Western University, CanadaLead Sponsor
254 Previous Clinical Trials
59,186 Total Patients Enrolled
Grace E Parraga, PhDPrincipal InvestigatorRobarts Research Institute, The University of Western Ontario
14 Previous Clinical Trials
1,264 Total Patients Enrolled

Media Library

MRI (Imaging) Clinical Trial Eligibility Overview. Trial Name: NCT02723474 — N/A
Lung Disease Research Study Groups: MRI at baseline and over time
Lung Disease Clinical Trial 2023: MRI Highlights & Side Effects. Trial Name: NCT02723474 — N/A
MRI (Imaging) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02723474 — N/A
~4 spots leftby Oct 2025